View ValuationBICO Group 将来の成長Future 基準チェック /16BICO Group利益と収益がそれぞれ年間97.6%と7.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-2.6% 97.7%なると予測されています。主要情報97.6%収益成長率97.67%EPS成長率Life Sciences 収益成長19.7%収益成長率7.7%将来の株主資本利益率-2.64%アナリストカバレッジLow最終更新日12 May 2026今後の成長に関する最新情報Major Estimate Revision • Feb 25Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from kr1.62b to kr1.58b. Losses expected to increase from kr2.01 per share to kr2.33. Life Sciences industry in Sweden expected to see average net income growth of 25% next year. Consensus price target broadly unchanged at kr30.67. Share price was steady at kr17.94 over the past week.Major Estimate Revision • Nov 11Consensus EPS estimates fall by 209%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr1.59b to kr1.57b. Losses expected to increase from kr6.93 per share to kr21.39. Life Sciences industry in Sweden expected to see average net income growth of 41% next year. Consensus price target of kr34.33 unchanged from last update. Share price fell 15% to kr20.38 over the past week.Price Target Changed • Oct 27Price target decreased by 8.4% to kr34.33Down from kr37.50, the current price target is an average from 3 analysts. New target price is 53% above last closing price of kr22.46. Stock is down 45% over the past year. The company is forecast to post a net loss per share of kr6.93 next year compared to a net loss per share of kr1.28 last year.Price Target Changed • Aug 20Price target decreased by 25% to kr52.00Down from kr69.67, the current price target is an average from 2 analysts. New target price is 98% above last closing price of kr26.22. Stock is down 45% over the past year. The company is forecast to post a net loss per share of kr6.90 next year compared to a net loss per share of kr1.28 last year.Breakeven Date Change • Apr 30Forecast breakeven date moved forward to 2026The 2 analysts covering BICO Group previously expected the company to break even in 2027. New consensus forecast suggests the company will make a profit of kr18.5m in 2026. Average annual earnings growth of 107% is required to achieve expected profit on schedule.Major Estimate Revision • Apr 24Consensus EPS estimates fall by 22%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr2.09b to kr2.07b. Losses expected to increase from kr1.92 per share to kr2.34. Life Sciences industry in Sweden expected to see average net income growth of 6.7% next year. Consensus price target up from kr64.67 to kr66.00. Share price rose 8.0% to kr38.72 over the past week.すべての更新を表示Recent updatesReported Earnings • May 02First quarter 2026 earnings: EPS misses analyst expectationsFirst quarter 2026 results: kr1.86 loss per share (improved from kr3.32 loss in 1Q 2025). Revenue: kr329.9m (down 1.5% from 1Q 2025). Net loss: kr131.3m (loss narrowed 44% from 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 86%. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.お知らせ • Apr 01BICO Group AB (publ) Announces Susan Tousi, Alexandra Gatzemeyer and Bengt Sjöholm Decline Re-Election as Members of the Board of DirectorsBICO Group AB (publ) announced that at the AGM to be held on May 7, 2026, Susan Tousi, Alexandra Gatzemeyer and Bengt Sjöholm have declined re-election as members of the Board of Directors.お知らせ • Mar 24BICO Group AB (publ) to Report Fiscal Year 2026 Results on Feb 17, 2027BICO Group AB (publ) announced that they will report fiscal year 2026 results on Feb 17, 2027Major Estimate Revision • Feb 25Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from kr1.62b to kr1.58b. Losses expected to increase from kr2.01 per share to kr2.33. Life Sciences industry in Sweden expected to see average net income growth of 25% next year. Consensus price target broadly unchanged at kr30.67. Share price was steady at kr17.94 over the past week.Reported Earnings • Feb 19Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: kr22.38 loss per share (further deteriorated from kr1.28 loss in FY 2024). Revenue: kr1.50b (down 23% from FY 2024). Net loss: kr1.58b (loss widened kr1.49b from FY 2024). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) exceeded analyst estimates by 30%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.分析記事 • Jan 22Is BICO Group (STO:BICO) Weighed On By Its Debt Load?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Dec 02Little Excitement Around BICO Group AB (publ)'s (STO:BICO) RevenuesBICO Group AB (publ)'s ( STO:BICO ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a buy right now...Major Estimate Revision • Nov 11Consensus EPS estimates fall by 209%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr1.59b to kr1.57b. Losses expected to increase from kr6.93 per share to kr21.39. Life Sciences industry in Sweden expected to see average net income growth of 41% next year. Consensus price target of kr34.33 unchanged from last update. Share price fell 15% to kr20.38 over the past week.Reported Earnings • Nov 05Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2025 results: kr15.68 loss per share (further deteriorated from kr3.49 loss in 3Q 2024). Revenue: kr386.9m (down 22% from 3Q 2024). Net loss: kr1.11b (loss widened 349% from 3Q 2024). Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.Price Target Changed • Oct 27Price target decreased by 8.4% to kr34.33Down from kr37.50, the current price target is an average from 3 analysts. New target price is 53% above last closing price of kr22.46. Stock is down 45% over the past year. The company is forecast to post a net loss per share of kr6.93 next year compared to a net loss per share of kr1.28 last year.お知らせ • Oct 11BICO Group AB (publ), Annual General Meeting, May 07, 2026BICO Group AB (publ), Annual General Meeting, May 07, 2026.Board Change • Sep 23Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Susan Tousi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Aug 24BICO Group AB (publ) (STO:BICO) Not Doing Enough For Some Investors As Its Shares Slump 34%The BICO Group AB (publ) ( STO:BICO ) share price has fared very poorly over the last month, falling by a substantial...Price Target Changed • Aug 20Price target decreased by 25% to kr52.00Down from kr69.67, the current price target is an average from 2 analysts. New target price is 98% above last closing price of kr26.22. Stock is down 45% over the past year. The company is forecast to post a net loss per share of kr6.90 next year compared to a net loss per share of kr1.28 last year.Reported Earnings • Aug 19First quarter 2025 earnings released: kr3.32 loss per share (vs kr0.27 loss in 1Q 2024)First quarter 2025 results: kr3.32 loss per share (further deteriorated from kr0.27 loss in 1Q 2024). Revenue: kr388.6m (down 17% from 1Q 2024). Net loss: kr234.0m (loss widened kr214.8m from 1Q 2024). Revenue is forecast to stay flat during the next 3 years compared to a 8.3% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.Buy Or Sell Opportunity • Aug 19Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to kr27.00. The fair value is estimated to be kr34.23, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.1% over the last 3 years. Earnings per share has declined by 37%.Buy Or Sell Opportunity • Jul 25Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 3.3% to kr40.00. The fair value is estimated to be kr33.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.1% over the last 3 years. Earnings per share has declined by 37%.New Risk • Jul 09New major risk - Revenue and earnings growthEarnings have declined by 42% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.お知らせ • Jul 03Sartorius Lab Holding GmbH completed the acquisition of MatTek Corporation from BICO Group AB (publ) (OM:BICO).Sartorius Lab Holding GmbH entered into an agreement to acquire MatTek Corporation from BICO Group AB (publ) (OM:BICO) for $80 million on April 4, 2025. The consideration is in cash and debt-free basis. The transaction includes the acquisition of Visikol Inc. During 2024, the business operations of Visikol were merged and operationally integrated into MatTek. For the period ending December 31, 2024, MatTek Corporation reported total revenue of $20 million. MatTek employs more than 80 people. The closing of the transaction is subject to customary regulatory approvals which are expected to be obtained during Q2 2025. Carnegie Investment Bank AB acted as financial advisor for BICO Group AB. Foley & Lardner LLP acted as legal advisor for BICO Group AB. PricewaterhouseCoopers Sweden acted as accountant for BICO Group AB. Led by Michael Bernhardt, Dean W. Sattler, Max Goodman, Alexander Rinne, and John Garces, Milbank LLP acted as legal advisor to Sartorius. Led by Matthias Zahn, Tobias Neukirchner, Kai Schmidt, Steven Wender, Sabrina Trümbach, Christoph Götz, Frank Breitenfeldt, Steve Ratmeyer, Kimberly Setz, and Susann Sturm, Rödl & Partner acted as financial advisor and accountant to Sartorius. Sartorius Lab Holding GmbH completed the acquisition of MatTek Corporation from BICO Group AB (publ) (OM:BICO) on July 1, 2025.お知らせ • Jun 25BICO Group AB Announces Change in General CounselBICO Group AB announced the appointment of Lars Risberg as General Counsel. He will succeed Andréas Joersjö, who has decided to leave BICO to pursue his career outside the Group. Lars Risberg has 20+ years of working as a General Counsel (GC) and attorney at law whereof the last four years as General Counsel for Vitrolife Group. Prior to that Lars worked as Regional Lead Counsel Northwest Europe for Dekra and as attorney at law at Awa Patent and Setterwalls Business Law firm. Lars Risberg will be joining BICO on June 26 and Andreas Joersjö will remain at BICO until August 31 for handover to Lars Risberg. As General Counsel Lars Risberg will report to BICO’s President and CEO and be a member of the Executive Management.Recent Insider Transactions • Jun 05Global Head of Human Resources recently bought kr61k worth of stockOn the 30th of May, Catharina Nordlund bought around 2k shares on-market at roughly kr35.70 per share. This transaction amounted to 85% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.お知らせ • May 09BICO Group AB (publ) Announces Board ChangesBICO Group AB (publ) at the AGM held on May 8, 2025, the shareholders approved Johan Westman were elected new members of the Board of Directors. The members of the Board of Directors, Ulrika Dellby and Helena Skåntorp, had announced that they were not available for re-election.New Risk • May 05New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr305m Forecast net loss in 2 years: kr29m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr29m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change).Reported Earnings • Apr 30First quarter 2025 earnings: EPS and revenues miss analyst expectationsFirst quarter 2025 results: kr3.32 loss per share (further deteriorated from kr0.40 loss in 1Q 2024). Revenue: kr388.6m (down 24% from 1Q 2024). Net loss: kr234.0m (loss widened kr205.8m from 1Q 2024). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) also missed analyst estimates by 107%. Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings.Breakeven Date Change • Apr 30Forecast breakeven date moved forward to 2026The 2 analysts covering BICO Group previously expected the company to break even in 2027. New consensus forecast suggests the company will make a profit of kr18.5m in 2026. Average annual earnings growth of 107% is required to achieve expected profit on schedule.Major Estimate Revision • Apr 24Consensus EPS estimates fall by 22%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr2.09b to kr2.07b. Losses expected to increase from kr1.92 per share to kr2.34. Life Sciences industry in Sweden expected to see average net income growth of 6.7% next year. Consensus price target up from kr64.67 to kr66.00. Share price rose 8.0% to kr38.72 over the past week.お知らせ • Apr 07BICO Group AB (publ) Announces Ulrika Dellby and Helena Skåntorp Decline Re-Election of the Board of DirectorsBICO Group AB (publ) at the Annual General Meeting to be held on May 8, 2025, Ulrika Dellby and Helena Skåntorp have declined re-election of the Board of Directors.Buy Or Sell Opportunity • Mar 26Now 20% undervaluedOver the last 90 days, the stock has risen 5.5% to kr34.30. The fair value is estimated to be kr42.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.0% over the last 3 years. Earnings per share has declined by 69%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 38% in the next 2 years.Reported Earnings • Mar 24Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: kr1.28 loss per share (improved from kr11.16 loss in FY 2023). Revenue: kr1.95b (down 3.2% from FY 2023). Net loss: kr90.1m (loss narrowed 89% from FY 2023). Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 98%. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 30 percentage points per year, which is a significant difference in performance.Major Estimate Revision • Mar 07Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr2.41b to kr2.09b. Forecast losses increased from -kr0.825 to -kr2.54 per share. Life Sciences industry in Sweden expected to see average net income decline 0.3% next year. Consensus price target down from kr75.00 to kr64.67. Share price rose 8.6% to kr39.78 over the past week.Breakeven Date Change • Mar 04Forecast breakeven date pushed back to 2027The 2 analysts covering BICO Group previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of kr79.8m in 2027. Average annual earnings growth of 51% is required to achieve expected profit on schedule.Reported Earnings • Feb 20Full year 2024 earnings released: kr1.28 loss per share (vs kr24.05 loss in FY 2023)Full year 2024 results: kr1.28 loss per share (improved from kr24.05 loss in FY 2023). Revenue: kr1.95b (down 19% from FY 2023). Net loss: kr90.1m (loss narrowed 95% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 9.2% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 31 percentage points per year, which is a significant difference in performance.New Risk • Feb 19New major risk - Revenue and earnings growthEarnings have declined by 72% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 72% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).Price Target Changed • Feb 19Price target decreased by 25% to kr75.00Down from kr100.00, the current price target is an average from 2 analysts. New target price is 70% above last closing price of kr44.12. Stock is down 6.6% over the past year. The company is forecast to post a net loss per share of kr4.19 next year compared to a net loss per share of kr24.04 last year.お知らせ • Nov 29Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million.Lab14 GmbH agreed to acquire Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million on November 21, 2024. Following net debt and working capital adjustments, the equity value amounts to €26 million (SEK 294 million). Net proceeds, following transaction expenses, will be used to reduce long term debt. Nanoscribe revenue LTM September 2024 amounted to SEK 230 million (€19.826 million) and the adjusted EBITDA margin to 12 percent according to IFRS. The transaction is expected to close during the fourth quarter 2024. Bryan, Garnier & Co acted as financial advisor and Clemens Höhn, Matthias Rothkopf, Jan D. Bonhage, Christian Dankerl, Markus Ernst and Sonnhild Draack of Hengeler Mueller acted as legal advisor to BICO Group. Lab14 GmbH completed the acquisition of Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) on November 28, 2024.Reported Earnings • Nov 27Third quarter 2024 earnings released: kr3.49 loss per share (vs kr1.00 loss in 3Q 2023)Third quarter 2024 results: kr3.49 loss per share (further deteriorated from kr1.00 loss in 3Q 2023). Revenue: kr495.5m (down 21% from 3Q 2023). Net loss: kr246.2m (loss widened 249% from 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance.Breakeven Date Change • Nov 16Forecast to breakeven in 2026The 2 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 87% per year to 2025. The company is expected to make a profit of kr100.4m in 2026. Average annual earnings growth of 130% is required to achieve expected profit on schedule.お知らせ • Oct 18+ 3 more updatesBICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025BICO Group AB (publ) announced that they will report fiscal year 2024 final results on Mar 20, 2025お知らせ • Oct 09BICO Group AB (publ), Annual General Meeting, May 08, 2025BICO Group AB (publ), Annual General Meeting, May 08, 2025.Major Estimate Revision • Sep 12Consensus EPS estimates fall by 18%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr2.43b to kr2.38b. Losses expected to increase from kr1.36 per share to kr1.61. Life Sciences industry in Sweden expected to see average net income growth of 88% next year. Consensus price target of kr120 unchanged from last update. Share price rose 6.7% to kr45.92 over the past week.Reported Earnings • Aug 21Second quarter 2024 earnings released: kr1.10 loss per share (vs kr12.73 loss in 2Q 2023)Second quarter 2024 results: kr1.10 loss per share (improved from kr12.73 loss in 2Q 2023). Revenue: kr534.0m (down 4.4% from 2Q 2023). Net loss: kr77.9m (loss narrowed 91% from 2Q 2023). Revenue is forecast to grow 9.9% p.a. on average during the next 2 years, compared to a 9.4% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 21 percentage points per year, which is a significant difference in performance.お知らせ • Jul 10BICO Group AB Announces Management ChangesBICO Group AB announced the appointment of Andréas Joersjö as General Counsel. He will succeed Lotta Bus who has decided to leave BICO to pursue her career outside the Group. Andréas Joersjö will assume his new position by mid-October 2024 at the latest. Andréas Joersjö has 15+ years of experience working in an international business environment as General Counsel, lawyer, and advisor. Before joining BICO, Andréas has worked for Swedish law firms Delphi and Hammarskiöld & Co, in connection with which he has had several in-house assignments with large companies in various businesses, as well as PwC, and most recently as General Counsel for Hedin Group. For Hedin Group he established and headed the Group's Legal & Compliance team and was also a member of the Executive Management. Andréas Joersjö will report to BICO's President and CEO and be a member of the Executive Management. He will assume his position by mid-October 2024 at the latest.Major Estimate Revision • Jun 13Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr2.49b to kr2.43b. Now expected to report a loss of kr1.06 per share instead of kr0.20 per share profit previously forecast. Life Sciences industry in Sweden expected to see average net income growth of 66% next year. Consensus price target down from kr133 to kr120. Share price was steady at kr44.92 over the past week.New Risk • Jun 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: kr1.6b Forecast net loss in 1 year: kr60m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (kr60m net loss next year). Share price has been volatile over the past 3 months (10% average weekly change).Breakeven Date Change • Jun 10No longer forecast to breakevenThe analyst covering BICO Group no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr31.3m in 2024. New forecast suggests the company will make a loss of kr131.0m in 2025.お知らせ • May 23BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of DirectorsBICO Group AB (publ) at its AGM held on May 20, 2024, approved the election of Alexandra Gatzemeyer as new member of the Board of Directors.Recent Insider Transactions • May 12President & CEO recently bought kr450k worth of stockOn the 7th of May, Maria Forss bought around 12k shares on-market at roughly kr37.34 per share. This transaction amounted to 43% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Maria's only on-market trade for the last 12 months.Reported Earnings • May 08First quarter 2024 earnings released: kr0.40 loss per share (vs kr1.67 loss in 1Q 2023)First quarter 2024 results: kr0.40 loss per share (improved from kr1.67 loss in 1Q 2023). Revenue: kr510.3m (down 5.1% from 1Q 2023). Net loss: kr28.2m (loss narrowed 76% from 1Q 2023). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 9.9% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance.お知らせ • Apr 19BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024BICO Group AB (publ) announced the appointment of Anders Fogelberg as Chief Commercial Officer (CCO). Commercial excellence has been defined as one of the top strategic priorities for BICO and this position is pivotal in setting and driving the strategy towards that target, i.e., in scaling the BICO business, increasing the commercialization efforts of the portfolio and further explore opportunities for collaborations and partnerships. Anders Fogelberg has 20+ years' experience of working with marketing and sales & business development in global organizations. He has extensive experience from different leadership positions foremost as a Managing Director for the SKF Group in Malaysia and Indonesia respectively. Before joining BICO, Anders has worked in the Med Tech industry now latest as Chief Marketing Officer and Head of Sales for Profundus and before that as CEO for Bellman & Symfon. Anders Fogelberg will assume his new position on June 13, 2024. The CCO role is newly established, will be a member of the Executive Management and report to BICO's CEO and President. The CCO will be main responsible for the commercial activities within the BICO Group and ensure cooperation between subsidiaries and that long-term partnerships are built with relevant partners throughout the global life science industry.お知らせ • Apr 16BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of DirectorsBICO Group AB (publ) at the Annual General Meeting on May 20, 2024, Gerry Mackay and Erik Gatenholm have declined re-election of the Board of Directors.お知らせ • Mar 15BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025BICO Group AB (publ) announced that they will report fiscal year 2024 results on Feb 19, 2025お知らせ • Mar 06+ 1 more updateBICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024BICO Group AB (publ) announced that they will report Q3, 2024 results on Nov 13, 2024Reported Earnings • Feb 21Full year 2023 earnings released: kr24.05 loss per share (vs kr12.94 loss in FY 2022)Full year 2023 results: kr24.05 loss per share (further deteriorated from kr12.94 loss in FY 2022). Revenue: kr2.58b (up 4.5% from FY 2022). Net loss: kr1.70b (loss widened 104% from FY 2022). Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.New Risk • Feb 21New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr435m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr435m free cash flow). Earnings have declined by 87% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).お知らせ • Jan 25BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HRBICO Group AB (publ) announced the appointment of Catharina Nordlund as Global Head of HR. The role will further strengthen the Executive Management and be responsible for shaping and executing BICO's global HR strategy in order to build a people and high-performance culture. Catharina Nordlund has 25+ years' experience of Human Resources (HR), Learning & Development as well as Sales and Marketing in global organizations. She has held various positions within the medtech and the life science industries at companies such as Cochlear Bone Anchored Solutions, Mölnlycke Health Care and Pfizer, and now latest as VP Global HR for Surgical Science. Her vast experience covers functional responsibility for HR as well as line manager positions within sales from the life science industry. Catharina Nordlund will be part of the Executive Management and report to the CEO and President.Recent Insider Transactions • Nov 17Group Chief Financial Officer recently bought kr860k worth of stockOn the 15th of November, Jacob Thordenberg bought around 18k shares on-market at roughly kr49.12 per share. This transaction increased Jacob's direct individual holding by 19x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jacob's only on-market trade for the last 12 months.お知らせ • Nov 15+ 4 more updatesBICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024BICO Group AB (publ) announced that they will report fiscal year 2023 results on Mar 15, 2024New Risk • Nov 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 82% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding).Price Target Changed • Sep 29Price target decreased by 8.1% to kr130Down from kr142, the current price target is an average from 2 analysts. New target price is 332% above last closing price of kr30.06. Stock is up 1.4% over the past year. The company is forecast to post a net loss per share of kr7.37 next year compared to a net loss per share of kr12.94 last year.Reported Earnings • Aug 23Second quarter 2023 earnings released: kr12.73 loss per share (vs kr0.68 profit in 2Q 2022)Second quarter 2023 results: kr12.73 loss per share (down from kr0.68 profit in 2Q 2022). Revenue: kr568.8m (down 3.1% from 2Q 2022). Net loss: kr898.3m (down kr941.9m from profit in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.お知らせ • Aug 22+ 1 more updateBICO Group AB (publ) Announces Chief Executive Officer ChangesBICO Group AB (publ) announced that Erik Gatenholm, after initiating discussions with the Board of Directors, has decided to step down as CEO of BICO Group. Maria Forss has been appointed as CEO. Maria Forss will assume office on November 27, 2023, or sooner. Maria Forss (born 1972) has extensive international experience from leading positions in both medtech and pharma companies, such as Vitrolife and AstraZeneca. The last years within Vitrolife Maria Forss has as the Senior Vice President led the Consumables Business Area and before that she was the Vice President of Business Development and Global Marketing. Maria Forss has successfully developed businesses through the whole value chain and in the whole product life cycle as well as acquisitions and integration of companies. In order to enable a seamless transition, Erik Gatenholm will remain in his current position until Maria Forss assumes as new President and CEO. To secure continuity Erik Gatenholm will, as major shareholder, also remain in his role as board member of BICO.分析記事 • Jul 01Here's Why BICO Group (STO:BICO) Can Afford Some DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...分析記事 • Jun 08The Market Doesn't Like What It Sees From BICO Group AB (publ)'s (STO:BICO) Earnings Yet As Shares Tumble 26%Unfortunately for some shareholders, the BICO Group AB (publ) ( STO:BICO ) share price has dived 26% in the last thirty...Recent Insider Transactions • May 15Independent Deputy Chairwoman recently bought kr59k worth of stockOn the 11th of May, Ulrika Dellby bought around 1k shares on-market at roughly kr59.26 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr100k. This was Ulrika's only on-market trade for the last 12 months.お知らせ • May 10BICO Group AB (publ) Elects Gerry Mackay to Its Board of DirectorsBICO Group AB (publ) at its Annual General Meeting held on 9 May 2023, elected Gerry Mackay to Its Board of Directors.Reported Earnings • May 08First quarter 2023 earnings released: kr1.67 loss per share (vs kr0.68 loss in 1Q 2022)First quarter 2023 results: kr1.67 loss per share (further deteriorated from kr0.68 loss in 1Q 2022). Revenue: kr537.6m (up 3.6% from 1Q 2022). Net loss: kr117.7m (loss widened 170% from 1Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.お知らせ • May 05BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024BICO Group AB (publ) announced that they will report fiscal year 2023 results on Feb 20, 2024Price Target Changed • Mar 03Price target decreased by 8.0% to kr133Down from kr144, the current price target is an average from 2 analysts. New target price is 96% above last closing price of kr67.62. Stock is down 57% over the past year. The company is forecast to post a net loss per share of kr0.82 next year compared to a net loss per share of kr12.94 last year.Recent Insider Transactions • Feb 28Independent Director recently bought kr100k worth of stockOn the 23rd of February, Helena Skantorp bought around 1k shares on-market at roughly kr69.03 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr7.1m more in shares than they have sold in the last 12 months.Buying Opportunity • Feb 22Now 38% undervalued after recent price dropOver the last 90 days, the stock is down 10%. The fair value is estimated to be kr102, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 82% over the last 3 years. Earnings per share has declined by 70%. Revenue is forecast to grow by 1.1% in a year. Earnings is forecast to grow by 92% in the next year.Recent Insider Transactions • Jan 14Independent Chairman of the Board recently sold kr8.4m worth of stockOn the 10th of January, Carsten Browall sold around 80k shares on-market at roughly kr104 per share. This transaction amounted to 71% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Carsten has been a net seller over the last 12 months, reducing personal holdings by kr7.4m.お知らせ • Jan 06BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023BICO Group AB announced the appointment of Marius Balger as Chief Operating Officer, as BICO continues to accelerate its growth journey across geographies and business strategies. Mr.Balger will be part of the Executive Management team and report directly to President & CEO Erik Gatenholm. As COO, Mr. Balger will take office 1 March 2023 and lead the strategic development of BICO’s operational efficiency and cost control. Mr. Balger brings nearly 20 years of experience in the global life science industry, most recently serving as Senior Vice President, Commercial Operations at Tecan AG, a public life science company headquartered in Zurich, where he has worked since 2017. Before Tecan AG, Mr. Balger had a long and esteemed career as CEO, successfully growing a global Contract Development and Manufacturing Organization for life science and in-vitro diagnostics laboratory instrumentation. In line with BICO's previously communicated strategy with a focus on cost control, operational efficiency, and decentralized organizational structure the Executive Management of BICO Group will, as of January 5, 2023, consist of the following people: President and CEO Erik Gatenholm; CTO Hector Martinez; CFO Jacob Thordenberg and SVP & General Counsel & HR Lotta Bus. As of 1 March 2023, both COO Marius Balger and Head of Corporate Development & M&A Artur Aira are included in the Executive Management team.お知らせ • Jan 03BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFOBICO Group AB announced the appointment of Jacob Thordenberg as Group CFO. Thordenberg will begin his employment in his new position as Group CFO, on January 2, 2023, and will be part of the company's executive management team. Jacob Thordenberg has a Master of Science in Corporate and Financial Management, and has more than ten years' experience from mergers and acquisitions from Deloitte, Telia and BICO Group AB. Most recently he comes from a role as Head of M&A at BICO, where he has been since December 2021. Thordenberg succeeds Mikael Engblom, who has been interim Group CFO since May 2022. Engblom will continue to advise the company on strategic projects.Price Target Changed • Dec 14Price target increased to kr144Up from kr124, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of kr139. Stock is down 47% over the past year. The company is forecast to post earnings per share of kr0.67 next year compared to a net loss per share of kr3.97 last year.Major Estimate Revision • Dec 02Consensus EPS estimates increase by 14%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from kr2.21b to kr2.33b. EPS estimate increased from kr1.97 to kr2.24 per share. Net income forecast to shrink 213% next year vs 25% growth forecast for Life Sciences industry in Sweden . Consensus price target down from kr153 to kr124. Share price rose 8.7% to kr77.16 over the past week.分析記事 • Dec 02Why BICO Group AB (publ) (STO:BICO) Could Be Worth WatchingWhile BICO Group AB (publ) ( STO:BICO ) might not be the most widely known stock at the moment, it saw a significant...Price Target Changed • Dec 01Price target decreased to kr124Down from kr150, the current price target is provided by 1 analyst. New target price is 59% above last closing price of kr78.10. Stock is down 72% over the past year. The company is forecast to post earnings per share of kr1.97 next year compared to a net loss per share of kr3.97 last year.Major Estimate Revision • Nov 18Consensus EPS estimates increase by 101%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from kr2.16b to kr2.21b. EPS estimate increased from kr0.98 to kr1.97 per share. Net income forecast to grow 364% next year vs 24% growth forecast for Life Sciences industry in Sweden. Consensus price target up from kr150 to kr153. Share price fell 10% to kr78.04 over the past week.Buying Opportunity • Nov 16Now 29% undervaluedOver the last 90 days, the stock is up 69%. The fair value is estimated to be kr103, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 85% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 59% in 2 years. Earnings is forecast to grow by 881% in the next 2 years.Price Target Changed • Nov 16Price target decreased to kr150Down from kr282, the current price target is provided by 1 analyst. New target price is 104% above last closing price of kr73.50. Stock is down 77% over the past year. The company is forecast to post earnings per share of kr0.98 next year compared to a net loss per share of kr3.97 last year.Board Change • Nov 16High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 4 experienced directors. No highly experienced directors. Independent Director Bengt Sjoholm is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Nov 10Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr623.2m (up 79% from 3Q 2021). Net income: kr66.4m (up kr170.6m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.お知らせ • Nov 10BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023BICO Group AB (publ) announced that they will report Q2, 2023 results on Jul 20, 2023Breakeven Date Change • Oct 22Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 112% is required to achieve expected profit on schedule.Reported Earnings • Aug 24Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr612.4m (up 88% from 2Q 2021). Net income: kr43.6m (up kr93.9m from 2Q 2021). Profit margin: 7.1% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 18%, compared to a 11% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.Breakeven Date Change • Jul 21Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 105% is required to achieve expected profit on schedule.業績と収益の成長予測OM:BICO - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281,839-4985126312/31/20271,689-112-1144312/31/20261,566-207-97-5633/31/20261,492-1,4771539N/A12/31/20251,497-1,5804368N/A9/30/20251,561-1,270159199N/A6/30/20251,543-424216275N/A3/31/20251,642-323176252N/A12/31/20241,727-10773158N/A9/30/20241,609-80348139N/A6/30/20241,828-583-3598N/A3/31/20241,941-729-98101N/A12/31/20232,010-788-113178N/A9/30/20232,213-497-435-53N/A6/30/20232,256-390-527-72N/A3/31/20232,297-117-643-140N/A12/31/20222,327-85-799-269N/A9/30/20222,27841-817-313N/A6/30/20221,995-130-872-457N/A3/31/20221,743-224-816-462N/A12/31/20211,378-228-676-409N/A9/30/2021993-188-529-321N/A6/30/2021744-96-328-150N/A3/31/2021460-50-156-34N/A12/31/2020369-36-160-59N/A8/31/2020236-62-154-72N/A5/31/2020213-49-146-70N/A2/29/2020197-24N/A-53N/A11/30/2019173-5N/A-31N/A8/31/20191351N/A-16N/A5/31/20191183N/A-16N/A2/28/2019974N/A-2N/A11/30/2018762N/A-12N/A8/31/2018611N/A-12N/A5/31/2018451N/A-6N/A2/28/201834-2N/A-7N/A11/30/201727-2N/A-8N/A8/31/201720-1N/A-1N/A8/31/20166-1N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BICO今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: BICO今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: BICO今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: BICOの収益 ( 7.7% ) Swedish市場 ( 0.01% ) よりも速いペースで成長すると予測されています。高い収益成長: BICOの収益 ( 7.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BICO 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/05 06:12終値2026/06/05 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BICO Group AB (publ) 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Kristofer Liljeberg-SvenssonDNB CarnegieLudvig LundgrenNordea MarketsFilip EinarssonRedeye
Major Estimate Revision • Feb 25Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from kr1.62b to kr1.58b. Losses expected to increase from kr2.01 per share to kr2.33. Life Sciences industry in Sweden expected to see average net income growth of 25% next year. Consensus price target broadly unchanged at kr30.67. Share price was steady at kr17.94 over the past week.
Major Estimate Revision • Nov 11Consensus EPS estimates fall by 209%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr1.59b to kr1.57b. Losses expected to increase from kr6.93 per share to kr21.39. Life Sciences industry in Sweden expected to see average net income growth of 41% next year. Consensus price target of kr34.33 unchanged from last update. Share price fell 15% to kr20.38 over the past week.
Price Target Changed • Oct 27Price target decreased by 8.4% to kr34.33Down from kr37.50, the current price target is an average from 3 analysts. New target price is 53% above last closing price of kr22.46. Stock is down 45% over the past year. The company is forecast to post a net loss per share of kr6.93 next year compared to a net loss per share of kr1.28 last year.
Price Target Changed • Aug 20Price target decreased by 25% to kr52.00Down from kr69.67, the current price target is an average from 2 analysts. New target price is 98% above last closing price of kr26.22. Stock is down 45% over the past year. The company is forecast to post a net loss per share of kr6.90 next year compared to a net loss per share of kr1.28 last year.
Breakeven Date Change • Apr 30Forecast breakeven date moved forward to 2026The 2 analysts covering BICO Group previously expected the company to break even in 2027. New consensus forecast suggests the company will make a profit of kr18.5m in 2026. Average annual earnings growth of 107% is required to achieve expected profit on schedule.
Major Estimate Revision • Apr 24Consensus EPS estimates fall by 22%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr2.09b to kr2.07b. Losses expected to increase from kr1.92 per share to kr2.34. Life Sciences industry in Sweden expected to see average net income growth of 6.7% next year. Consensus price target up from kr64.67 to kr66.00. Share price rose 8.0% to kr38.72 over the past week.
Reported Earnings • May 02First quarter 2026 earnings: EPS misses analyst expectationsFirst quarter 2026 results: kr1.86 loss per share (improved from kr3.32 loss in 1Q 2025). Revenue: kr329.9m (down 1.5% from 1Q 2025). Net loss: kr131.3m (loss narrowed 44% from 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 86%. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 01BICO Group AB (publ) Announces Susan Tousi, Alexandra Gatzemeyer and Bengt Sjöholm Decline Re-Election as Members of the Board of DirectorsBICO Group AB (publ) announced that at the AGM to be held on May 7, 2026, Susan Tousi, Alexandra Gatzemeyer and Bengt Sjöholm have declined re-election as members of the Board of Directors.
お知らせ • Mar 24BICO Group AB (publ) to Report Fiscal Year 2026 Results on Feb 17, 2027BICO Group AB (publ) announced that they will report fiscal year 2026 results on Feb 17, 2027
Major Estimate Revision • Feb 25Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from kr1.62b to kr1.58b. Losses expected to increase from kr2.01 per share to kr2.33. Life Sciences industry in Sweden expected to see average net income growth of 25% next year. Consensus price target broadly unchanged at kr30.67. Share price was steady at kr17.94 over the past week.
Reported Earnings • Feb 19Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: kr22.38 loss per share (further deteriorated from kr1.28 loss in FY 2024). Revenue: kr1.50b (down 23% from FY 2024). Net loss: kr1.58b (loss widened kr1.49b from FY 2024). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) exceeded analyst estimates by 30%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.
分析記事 • Jan 22Is BICO Group (STO:BICO) Weighed On By Its Debt Load?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Dec 02Little Excitement Around BICO Group AB (publ)'s (STO:BICO) RevenuesBICO Group AB (publ)'s ( STO:BICO ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a buy right now...
Major Estimate Revision • Nov 11Consensus EPS estimates fall by 209%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr1.59b to kr1.57b. Losses expected to increase from kr6.93 per share to kr21.39. Life Sciences industry in Sweden expected to see average net income growth of 41% next year. Consensus price target of kr34.33 unchanged from last update. Share price fell 15% to kr20.38 over the past week.
Reported Earnings • Nov 05Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2025 results: kr15.68 loss per share (further deteriorated from kr3.49 loss in 3Q 2024). Revenue: kr386.9m (down 22% from 3Q 2024). Net loss: kr1.11b (loss widened 349% from 3Q 2024). Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.
Price Target Changed • Oct 27Price target decreased by 8.4% to kr34.33Down from kr37.50, the current price target is an average from 3 analysts. New target price is 53% above last closing price of kr22.46. Stock is down 45% over the past year. The company is forecast to post a net loss per share of kr6.93 next year compared to a net loss per share of kr1.28 last year.
お知らせ • Oct 11BICO Group AB (publ), Annual General Meeting, May 07, 2026BICO Group AB (publ), Annual General Meeting, May 07, 2026.
Board Change • Sep 23Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Susan Tousi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Aug 24BICO Group AB (publ) (STO:BICO) Not Doing Enough For Some Investors As Its Shares Slump 34%The BICO Group AB (publ) ( STO:BICO ) share price has fared very poorly over the last month, falling by a substantial...
Price Target Changed • Aug 20Price target decreased by 25% to kr52.00Down from kr69.67, the current price target is an average from 2 analysts. New target price is 98% above last closing price of kr26.22. Stock is down 45% over the past year. The company is forecast to post a net loss per share of kr6.90 next year compared to a net loss per share of kr1.28 last year.
Reported Earnings • Aug 19First quarter 2025 earnings released: kr3.32 loss per share (vs kr0.27 loss in 1Q 2024)First quarter 2025 results: kr3.32 loss per share (further deteriorated from kr0.27 loss in 1Q 2024). Revenue: kr388.6m (down 17% from 1Q 2024). Net loss: kr234.0m (loss widened kr214.8m from 1Q 2024). Revenue is forecast to stay flat during the next 3 years compared to a 8.3% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
Buy Or Sell Opportunity • Aug 19Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to kr27.00. The fair value is estimated to be kr34.23, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.1% over the last 3 years. Earnings per share has declined by 37%.
Buy Or Sell Opportunity • Jul 25Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 3.3% to kr40.00. The fair value is estimated to be kr33.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.1% over the last 3 years. Earnings per share has declined by 37%.
New Risk • Jul 09New major risk - Revenue and earnings growthEarnings have declined by 42% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
お知らせ • Jul 03Sartorius Lab Holding GmbH completed the acquisition of MatTek Corporation from BICO Group AB (publ) (OM:BICO).Sartorius Lab Holding GmbH entered into an agreement to acquire MatTek Corporation from BICO Group AB (publ) (OM:BICO) for $80 million on April 4, 2025. The consideration is in cash and debt-free basis. The transaction includes the acquisition of Visikol Inc. During 2024, the business operations of Visikol were merged and operationally integrated into MatTek. For the period ending December 31, 2024, MatTek Corporation reported total revenue of $20 million. MatTek employs more than 80 people. The closing of the transaction is subject to customary regulatory approvals which are expected to be obtained during Q2 2025. Carnegie Investment Bank AB acted as financial advisor for BICO Group AB. Foley & Lardner LLP acted as legal advisor for BICO Group AB. PricewaterhouseCoopers Sweden acted as accountant for BICO Group AB. Led by Michael Bernhardt, Dean W. Sattler, Max Goodman, Alexander Rinne, and John Garces, Milbank LLP acted as legal advisor to Sartorius. Led by Matthias Zahn, Tobias Neukirchner, Kai Schmidt, Steven Wender, Sabrina Trümbach, Christoph Götz, Frank Breitenfeldt, Steve Ratmeyer, Kimberly Setz, and Susann Sturm, Rödl & Partner acted as financial advisor and accountant to Sartorius. Sartorius Lab Holding GmbH completed the acquisition of MatTek Corporation from BICO Group AB (publ) (OM:BICO) on July 1, 2025.
お知らせ • Jun 25BICO Group AB Announces Change in General CounselBICO Group AB announced the appointment of Lars Risberg as General Counsel. He will succeed Andréas Joersjö, who has decided to leave BICO to pursue his career outside the Group. Lars Risberg has 20+ years of working as a General Counsel (GC) and attorney at law whereof the last four years as General Counsel for Vitrolife Group. Prior to that Lars worked as Regional Lead Counsel Northwest Europe for Dekra and as attorney at law at Awa Patent and Setterwalls Business Law firm. Lars Risberg will be joining BICO on June 26 and Andreas Joersjö will remain at BICO until August 31 for handover to Lars Risberg. As General Counsel Lars Risberg will report to BICO’s President and CEO and be a member of the Executive Management.
Recent Insider Transactions • Jun 05Global Head of Human Resources recently bought kr61k worth of stockOn the 30th of May, Catharina Nordlund bought around 2k shares on-market at roughly kr35.70 per share. This transaction amounted to 85% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
お知らせ • May 09BICO Group AB (publ) Announces Board ChangesBICO Group AB (publ) at the AGM held on May 8, 2025, the shareholders approved Johan Westman were elected new members of the Board of Directors. The members of the Board of Directors, Ulrika Dellby and Helena Skåntorp, had announced that they were not available for re-election.
New Risk • May 05New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr305m Forecast net loss in 2 years: kr29m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr29m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change).
Reported Earnings • Apr 30First quarter 2025 earnings: EPS and revenues miss analyst expectationsFirst quarter 2025 results: kr3.32 loss per share (further deteriorated from kr0.40 loss in 1Q 2024). Revenue: kr388.6m (down 24% from 1Q 2024). Net loss: kr234.0m (loss widened kr205.8m from 1Q 2024). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) also missed analyst estimates by 107%. Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings.
Breakeven Date Change • Apr 30Forecast breakeven date moved forward to 2026The 2 analysts covering BICO Group previously expected the company to break even in 2027. New consensus forecast suggests the company will make a profit of kr18.5m in 2026. Average annual earnings growth of 107% is required to achieve expected profit on schedule.
Major Estimate Revision • Apr 24Consensus EPS estimates fall by 22%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr2.09b to kr2.07b. Losses expected to increase from kr1.92 per share to kr2.34. Life Sciences industry in Sweden expected to see average net income growth of 6.7% next year. Consensus price target up from kr64.67 to kr66.00. Share price rose 8.0% to kr38.72 over the past week.
お知らせ • Apr 07BICO Group AB (publ) Announces Ulrika Dellby and Helena Skåntorp Decline Re-Election of the Board of DirectorsBICO Group AB (publ) at the Annual General Meeting to be held on May 8, 2025, Ulrika Dellby and Helena Skåntorp have declined re-election of the Board of Directors.
Buy Or Sell Opportunity • Mar 26Now 20% undervaluedOver the last 90 days, the stock has risen 5.5% to kr34.30. The fair value is estimated to be kr42.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.0% over the last 3 years. Earnings per share has declined by 69%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 38% in the next 2 years.
Reported Earnings • Mar 24Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: kr1.28 loss per share (improved from kr11.16 loss in FY 2023). Revenue: kr1.95b (down 3.2% from FY 2023). Net loss: kr90.1m (loss narrowed 89% from FY 2023). Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 98%. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 30 percentage points per year, which is a significant difference in performance.
Major Estimate Revision • Mar 07Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr2.41b to kr2.09b. Forecast losses increased from -kr0.825 to -kr2.54 per share. Life Sciences industry in Sweden expected to see average net income decline 0.3% next year. Consensus price target down from kr75.00 to kr64.67. Share price rose 8.6% to kr39.78 over the past week.
Breakeven Date Change • Mar 04Forecast breakeven date pushed back to 2027The 2 analysts covering BICO Group previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of kr79.8m in 2027. Average annual earnings growth of 51% is required to achieve expected profit on schedule.
Reported Earnings • Feb 20Full year 2024 earnings released: kr1.28 loss per share (vs kr24.05 loss in FY 2023)Full year 2024 results: kr1.28 loss per share (improved from kr24.05 loss in FY 2023). Revenue: kr1.95b (down 19% from FY 2023). Net loss: kr90.1m (loss narrowed 95% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 9.2% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 31 percentage points per year, which is a significant difference in performance.
New Risk • Feb 19New major risk - Revenue and earnings growthEarnings have declined by 72% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 72% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
Price Target Changed • Feb 19Price target decreased by 25% to kr75.00Down from kr100.00, the current price target is an average from 2 analysts. New target price is 70% above last closing price of kr44.12. Stock is down 6.6% over the past year. The company is forecast to post a net loss per share of kr4.19 next year compared to a net loss per share of kr24.04 last year.
お知らせ • Nov 29Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million.Lab14 GmbH agreed to acquire Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million on November 21, 2024. Following net debt and working capital adjustments, the equity value amounts to €26 million (SEK 294 million). Net proceeds, following transaction expenses, will be used to reduce long term debt. Nanoscribe revenue LTM September 2024 amounted to SEK 230 million (€19.826 million) and the adjusted EBITDA margin to 12 percent according to IFRS. The transaction is expected to close during the fourth quarter 2024. Bryan, Garnier & Co acted as financial advisor and Clemens Höhn, Matthias Rothkopf, Jan D. Bonhage, Christian Dankerl, Markus Ernst and Sonnhild Draack of Hengeler Mueller acted as legal advisor to BICO Group. Lab14 GmbH completed the acquisition of Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) on November 28, 2024.
Reported Earnings • Nov 27Third quarter 2024 earnings released: kr3.49 loss per share (vs kr1.00 loss in 3Q 2023)Third quarter 2024 results: kr3.49 loss per share (further deteriorated from kr1.00 loss in 3Q 2023). Revenue: kr495.5m (down 21% from 3Q 2023). Net loss: kr246.2m (loss widened 249% from 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance.
Breakeven Date Change • Nov 16Forecast to breakeven in 2026The 2 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 87% per year to 2025. The company is expected to make a profit of kr100.4m in 2026. Average annual earnings growth of 130% is required to achieve expected profit on schedule.
お知らせ • Oct 18+ 3 more updatesBICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025BICO Group AB (publ) announced that they will report fiscal year 2024 final results on Mar 20, 2025
お知らせ • Oct 09BICO Group AB (publ), Annual General Meeting, May 08, 2025BICO Group AB (publ), Annual General Meeting, May 08, 2025.
Major Estimate Revision • Sep 12Consensus EPS estimates fall by 18%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr2.43b to kr2.38b. Losses expected to increase from kr1.36 per share to kr1.61. Life Sciences industry in Sweden expected to see average net income growth of 88% next year. Consensus price target of kr120 unchanged from last update. Share price rose 6.7% to kr45.92 over the past week.
Reported Earnings • Aug 21Second quarter 2024 earnings released: kr1.10 loss per share (vs kr12.73 loss in 2Q 2023)Second quarter 2024 results: kr1.10 loss per share (improved from kr12.73 loss in 2Q 2023). Revenue: kr534.0m (down 4.4% from 2Q 2023). Net loss: kr77.9m (loss narrowed 91% from 2Q 2023). Revenue is forecast to grow 9.9% p.a. on average during the next 2 years, compared to a 9.4% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 21 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 10BICO Group AB Announces Management ChangesBICO Group AB announced the appointment of Andréas Joersjö as General Counsel. He will succeed Lotta Bus who has decided to leave BICO to pursue her career outside the Group. Andréas Joersjö will assume his new position by mid-October 2024 at the latest. Andréas Joersjö has 15+ years of experience working in an international business environment as General Counsel, lawyer, and advisor. Before joining BICO, Andréas has worked for Swedish law firms Delphi and Hammarskiöld & Co, in connection with which he has had several in-house assignments with large companies in various businesses, as well as PwC, and most recently as General Counsel for Hedin Group. For Hedin Group he established and headed the Group's Legal & Compliance team and was also a member of the Executive Management. Andréas Joersjö will report to BICO's President and CEO and be a member of the Executive Management. He will assume his position by mid-October 2024 at the latest.
Major Estimate Revision • Jun 13Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr2.49b to kr2.43b. Now expected to report a loss of kr1.06 per share instead of kr0.20 per share profit previously forecast. Life Sciences industry in Sweden expected to see average net income growth of 66% next year. Consensus price target down from kr133 to kr120. Share price was steady at kr44.92 over the past week.
New Risk • Jun 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: kr1.6b Forecast net loss in 1 year: kr60m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (kr60m net loss next year). Share price has been volatile over the past 3 months (10% average weekly change).
Breakeven Date Change • Jun 10No longer forecast to breakevenThe analyst covering BICO Group no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr31.3m in 2024. New forecast suggests the company will make a loss of kr131.0m in 2025.
お知らせ • May 23BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of DirectorsBICO Group AB (publ) at its AGM held on May 20, 2024, approved the election of Alexandra Gatzemeyer as new member of the Board of Directors.
Recent Insider Transactions • May 12President & CEO recently bought kr450k worth of stockOn the 7th of May, Maria Forss bought around 12k shares on-market at roughly kr37.34 per share. This transaction amounted to 43% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Maria's only on-market trade for the last 12 months.
Reported Earnings • May 08First quarter 2024 earnings released: kr0.40 loss per share (vs kr1.67 loss in 1Q 2023)First quarter 2024 results: kr0.40 loss per share (improved from kr1.67 loss in 1Q 2023). Revenue: kr510.3m (down 5.1% from 1Q 2023). Net loss: kr28.2m (loss narrowed 76% from 1Q 2023). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 9.9% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 19BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024BICO Group AB (publ) announced the appointment of Anders Fogelberg as Chief Commercial Officer (CCO). Commercial excellence has been defined as one of the top strategic priorities for BICO and this position is pivotal in setting and driving the strategy towards that target, i.e., in scaling the BICO business, increasing the commercialization efforts of the portfolio and further explore opportunities for collaborations and partnerships. Anders Fogelberg has 20+ years' experience of working with marketing and sales & business development in global organizations. He has extensive experience from different leadership positions foremost as a Managing Director for the SKF Group in Malaysia and Indonesia respectively. Before joining BICO, Anders has worked in the Med Tech industry now latest as Chief Marketing Officer and Head of Sales for Profundus and before that as CEO for Bellman & Symfon. Anders Fogelberg will assume his new position on June 13, 2024. The CCO role is newly established, will be a member of the Executive Management and report to BICO's CEO and President. The CCO will be main responsible for the commercial activities within the BICO Group and ensure cooperation between subsidiaries and that long-term partnerships are built with relevant partners throughout the global life science industry.
お知らせ • Apr 16BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of DirectorsBICO Group AB (publ) at the Annual General Meeting on May 20, 2024, Gerry Mackay and Erik Gatenholm have declined re-election of the Board of Directors.
お知らせ • Mar 15BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025BICO Group AB (publ) announced that they will report fiscal year 2024 results on Feb 19, 2025
お知らせ • Mar 06+ 1 more updateBICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024BICO Group AB (publ) announced that they will report Q3, 2024 results on Nov 13, 2024
Reported Earnings • Feb 21Full year 2023 earnings released: kr24.05 loss per share (vs kr12.94 loss in FY 2022)Full year 2023 results: kr24.05 loss per share (further deteriorated from kr12.94 loss in FY 2022). Revenue: kr2.58b (up 4.5% from FY 2022). Net loss: kr1.70b (loss widened 104% from FY 2022). Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.
New Risk • Feb 21New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr435m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr435m free cash flow). Earnings have declined by 87% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
お知らせ • Jan 25BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HRBICO Group AB (publ) announced the appointment of Catharina Nordlund as Global Head of HR. The role will further strengthen the Executive Management and be responsible for shaping and executing BICO's global HR strategy in order to build a people and high-performance culture. Catharina Nordlund has 25+ years' experience of Human Resources (HR), Learning & Development as well as Sales and Marketing in global organizations. She has held various positions within the medtech and the life science industries at companies such as Cochlear Bone Anchored Solutions, Mölnlycke Health Care and Pfizer, and now latest as VP Global HR for Surgical Science. Her vast experience covers functional responsibility for HR as well as line manager positions within sales from the life science industry. Catharina Nordlund will be part of the Executive Management and report to the CEO and President.
Recent Insider Transactions • Nov 17Group Chief Financial Officer recently bought kr860k worth of stockOn the 15th of November, Jacob Thordenberg bought around 18k shares on-market at roughly kr49.12 per share. This transaction increased Jacob's direct individual holding by 19x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jacob's only on-market trade for the last 12 months.
お知らせ • Nov 15+ 4 more updatesBICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024BICO Group AB (publ) announced that they will report fiscal year 2023 results on Mar 15, 2024
New Risk • Nov 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 82% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding).
Price Target Changed • Sep 29Price target decreased by 8.1% to kr130Down from kr142, the current price target is an average from 2 analysts. New target price is 332% above last closing price of kr30.06. Stock is up 1.4% over the past year. The company is forecast to post a net loss per share of kr7.37 next year compared to a net loss per share of kr12.94 last year.
Reported Earnings • Aug 23Second quarter 2023 earnings released: kr12.73 loss per share (vs kr0.68 profit in 2Q 2022)Second quarter 2023 results: kr12.73 loss per share (down from kr0.68 profit in 2Q 2022). Revenue: kr568.8m (down 3.1% from 2Q 2022). Net loss: kr898.3m (down kr941.9m from profit in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 22+ 1 more updateBICO Group AB (publ) Announces Chief Executive Officer ChangesBICO Group AB (publ) announced that Erik Gatenholm, after initiating discussions with the Board of Directors, has decided to step down as CEO of BICO Group. Maria Forss has been appointed as CEO. Maria Forss will assume office on November 27, 2023, or sooner. Maria Forss (born 1972) has extensive international experience from leading positions in both medtech and pharma companies, such as Vitrolife and AstraZeneca. The last years within Vitrolife Maria Forss has as the Senior Vice President led the Consumables Business Area and before that she was the Vice President of Business Development and Global Marketing. Maria Forss has successfully developed businesses through the whole value chain and in the whole product life cycle as well as acquisitions and integration of companies. In order to enable a seamless transition, Erik Gatenholm will remain in his current position until Maria Forss assumes as new President and CEO. To secure continuity Erik Gatenholm will, as major shareholder, also remain in his role as board member of BICO.
分析記事 • Jul 01Here's Why BICO Group (STO:BICO) Can Afford Some DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
分析記事 • Jun 08The Market Doesn't Like What It Sees From BICO Group AB (publ)'s (STO:BICO) Earnings Yet As Shares Tumble 26%Unfortunately for some shareholders, the BICO Group AB (publ) ( STO:BICO ) share price has dived 26% in the last thirty...
Recent Insider Transactions • May 15Independent Deputy Chairwoman recently bought kr59k worth of stockOn the 11th of May, Ulrika Dellby bought around 1k shares on-market at roughly kr59.26 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr100k. This was Ulrika's only on-market trade for the last 12 months.
お知らせ • May 10BICO Group AB (publ) Elects Gerry Mackay to Its Board of DirectorsBICO Group AB (publ) at its Annual General Meeting held on 9 May 2023, elected Gerry Mackay to Its Board of Directors.
Reported Earnings • May 08First quarter 2023 earnings released: kr1.67 loss per share (vs kr0.68 loss in 1Q 2022)First quarter 2023 results: kr1.67 loss per share (further deteriorated from kr0.68 loss in 1Q 2022). Revenue: kr537.6m (up 3.6% from 1Q 2022). Net loss: kr117.7m (loss widened 170% from 1Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.
お知らせ • May 05BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024BICO Group AB (publ) announced that they will report fiscal year 2023 results on Feb 20, 2024
Price Target Changed • Mar 03Price target decreased by 8.0% to kr133Down from kr144, the current price target is an average from 2 analysts. New target price is 96% above last closing price of kr67.62. Stock is down 57% over the past year. The company is forecast to post a net loss per share of kr0.82 next year compared to a net loss per share of kr12.94 last year.
Recent Insider Transactions • Feb 28Independent Director recently bought kr100k worth of stockOn the 23rd of February, Helena Skantorp bought around 1k shares on-market at roughly kr69.03 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr7.1m more in shares than they have sold in the last 12 months.
Buying Opportunity • Feb 22Now 38% undervalued after recent price dropOver the last 90 days, the stock is down 10%. The fair value is estimated to be kr102, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 82% over the last 3 years. Earnings per share has declined by 70%. Revenue is forecast to grow by 1.1% in a year. Earnings is forecast to grow by 92% in the next year.
Recent Insider Transactions • Jan 14Independent Chairman of the Board recently sold kr8.4m worth of stockOn the 10th of January, Carsten Browall sold around 80k shares on-market at roughly kr104 per share. This transaction amounted to 71% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Carsten has been a net seller over the last 12 months, reducing personal holdings by kr7.4m.
お知らせ • Jan 06BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023BICO Group AB announced the appointment of Marius Balger as Chief Operating Officer, as BICO continues to accelerate its growth journey across geographies and business strategies. Mr.Balger will be part of the Executive Management team and report directly to President & CEO Erik Gatenholm. As COO, Mr. Balger will take office 1 March 2023 and lead the strategic development of BICO’s operational efficiency and cost control. Mr. Balger brings nearly 20 years of experience in the global life science industry, most recently serving as Senior Vice President, Commercial Operations at Tecan AG, a public life science company headquartered in Zurich, where he has worked since 2017. Before Tecan AG, Mr. Balger had a long and esteemed career as CEO, successfully growing a global Contract Development and Manufacturing Organization for life science and in-vitro diagnostics laboratory instrumentation. In line with BICO's previously communicated strategy with a focus on cost control, operational efficiency, and decentralized organizational structure the Executive Management of BICO Group will, as of January 5, 2023, consist of the following people: President and CEO Erik Gatenholm; CTO Hector Martinez; CFO Jacob Thordenberg and SVP & General Counsel & HR Lotta Bus. As of 1 March 2023, both COO Marius Balger and Head of Corporate Development & M&A Artur Aira are included in the Executive Management team.
お知らせ • Jan 03BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFOBICO Group AB announced the appointment of Jacob Thordenberg as Group CFO. Thordenberg will begin his employment in his new position as Group CFO, on January 2, 2023, and will be part of the company's executive management team. Jacob Thordenberg has a Master of Science in Corporate and Financial Management, and has more than ten years' experience from mergers and acquisitions from Deloitte, Telia and BICO Group AB. Most recently he comes from a role as Head of M&A at BICO, where he has been since December 2021. Thordenberg succeeds Mikael Engblom, who has been interim Group CFO since May 2022. Engblom will continue to advise the company on strategic projects.
Price Target Changed • Dec 14Price target increased to kr144Up from kr124, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of kr139. Stock is down 47% over the past year. The company is forecast to post earnings per share of kr0.67 next year compared to a net loss per share of kr3.97 last year.
Major Estimate Revision • Dec 02Consensus EPS estimates increase by 14%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from kr2.21b to kr2.33b. EPS estimate increased from kr1.97 to kr2.24 per share. Net income forecast to shrink 213% next year vs 25% growth forecast for Life Sciences industry in Sweden . Consensus price target down from kr153 to kr124. Share price rose 8.7% to kr77.16 over the past week.
分析記事 • Dec 02Why BICO Group AB (publ) (STO:BICO) Could Be Worth WatchingWhile BICO Group AB (publ) ( STO:BICO ) might not be the most widely known stock at the moment, it saw a significant...
Price Target Changed • Dec 01Price target decreased to kr124Down from kr150, the current price target is provided by 1 analyst. New target price is 59% above last closing price of kr78.10. Stock is down 72% over the past year. The company is forecast to post earnings per share of kr1.97 next year compared to a net loss per share of kr3.97 last year.
Major Estimate Revision • Nov 18Consensus EPS estimates increase by 101%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from kr2.16b to kr2.21b. EPS estimate increased from kr0.98 to kr1.97 per share. Net income forecast to grow 364% next year vs 24% growth forecast for Life Sciences industry in Sweden. Consensus price target up from kr150 to kr153. Share price fell 10% to kr78.04 over the past week.
Buying Opportunity • Nov 16Now 29% undervaluedOver the last 90 days, the stock is up 69%. The fair value is estimated to be kr103, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 85% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 59% in 2 years. Earnings is forecast to grow by 881% in the next 2 years.
Price Target Changed • Nov 16Price target decreased to kr150Down from kr282, the current price target is provided by 1 analyst. New target price is 104% above last closing price of kr73.50. Stock is down 77% over the past year. The company is forecast to post earnings per share of kr0.98 next year compared to a net loss per share of kr3.97 last year.
Board Change • Nov 16High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 4 experienced directors. No highly experienced directors. Independent Director Bengt Sjoholm is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Nov 10Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr623.2m (up 79% from 3Q 2021). Net income: kr66.4m (up kr170.6m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 10BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023BICO Group AB (publ) announced that they will report Q2, 2023 results on Jul 20, 2023
Breakeven Date Change • Oct 22Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 112% is required to achieve expected profit on schedule.
Reported Earnings • Aug 24Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr612.4m (up 88% from 2Q 2021). Net income: kr43.6m (up kr93.9m from 2Q 2021). Profit margin: 7.1% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 18%, compared to a 11% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
Breakeven Date Change • Jul 21Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 105% is required to achieve expected profit on schedule.